Journal article icon

Journal article

Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma

Abstract:

Introduction

Until recently, adjuvant treatment options for stage III and IV resectable melanoma have been limited.

Patients were often managed through routine surveillance. The phase III randomised controlled trial (RCT) CheckMate 238 (238) demonstrated the safety and efficacy of nivolumab as an adjuvant treatment for melanoma in patients with stage IIIB/C or IV disease (American Joint Committee on Cancer [AJCC], 7th edition) versus ipilimumab. The study objective ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.ejca.2020.03.011

Authors


Publisher:
Elsevier
Journal:
European Journal of Cancer More from this journal
Volume:
132
Pages:
176-186
Publication date:
2020-05-04
Acceptance date:
2020-03-18
DOI:
ISSN:
0959-8049
Language:
English
Keywords:
Pubs id:
1096041
Local pid:
pubs:1096041
Deposit date:
2020-03-23

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP